Steadymed Ltd (NASDAQ:STDY) CFO David W. Nassif sold 22,157 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $4.46, for a total value of $98,820.22. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of STDY opened at $4.73 on Friday. The company has a market capitalization of $126.36 million, a PE ratio of -10.99 and a beta of 0.47. Steadymed Ltd has a 52 week low of $2.60 and a 52 week high of $6.45.
Steadymed (NASDAQ:STDY) last issued its earnings results on Tuesday, August 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.17). Steadymed had a negative return on equity of 94.69% and a negative net margin of 2,177.00%. research analysts expect that Steadymed Ltd will post -0.76 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Western Standard LLC bought a new stake in shares of Steadymed in the 2nd quarter worth approximately $385,000. Renaissance Technologies LLC raised its stake in Steadymed by 275.1% during the 2nd quarter. Renaissance Technologies LLC now owns 298,562 shares of the company’s stock valued at $1,344,000 after acquiring an additional 218,962 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Steadymed in the 2nd quarter worth $1,104,000. Institutional investors own 43.76% of the company’s stock.
SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology.
Featured Article: Hedge Funds
Receive News & Ratings for Steadymed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steadymed and related companies with MarketBeat.com's FREE daily email newsletter.